TENX

Tenax Therapeutics, Inc. [TENX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TENX Stock Summary

Top 10 Correlated Stocks

TENX


In the News

07:52 04 Feb 2023 TENX

Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?

Tenax Therapeutics (NASDAQ: TENX ) stock is rocketing higher on Thursday after getting an update on one of its patents. That includes a Notice of Allowance from the USPTO.

11:01 04 Feb 2023 TENX

Why Is Tenax Therapeutics (TENX) Stock On the Move Today?

Tenax Therapeutics (NASDAQ: TENX ) stock is on the move Wednesday after the company announced plans for a reverse stock split. At 5:00 p.m.

02:00 04 Feb 2023 TENX

7 Cheap Penny Stocks To Buy For Under $1 Right Now

Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:40 04 Feb 2023 TENX

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

07:56 04 Feb 2023 TENX

TENX Stock Price Increases Over 12% Pre-Market: Why It Happened

The stock price of Tenax Therapeutics Inc (NASDAQ: TENX) increased by over 12% pre-market. This is why it happened.

04:52 04 Feb 2023 TENX

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX

New York, New York--(Newsfile Corp. - June 7, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

05:15 04 Feb 2023 TENX

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

10:52 04 Feb 2023 TENX

Tenax Therapeutics Stock Price Increased Over 35% Intraday: Why It Happened

The stock price of Tenax Therapeutics (NASDAQ: TENX) increased by over 35% during intraday trading. This is why it happened.

04:45 04 Feb 2023 TENX

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.

04:45 04 Feb 2023 TENX

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update

TENX Financial details

Company Rating
Neutral
Market Cap
5.13M
Income
-11.71M
Revenue
0
Book val./share
0.15
Cash/share
0.14
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
27 Mar 2023
P/E
-3.94
Forward P/E
-
PEG
-0.66
P/S
-
P/B
11.65
P/C
12.5
P/FCF
-3.69
Quick Ratio
5.52
Current Ratio
6.54
Debt / Equity
0.02
LT Debt / Equity
0.02
-
-
EPS (TTM)
2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-218.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-9.25%
SMA50
-8.44%
SMA100
-50.72%
Inst Own
25.9%
Inst Trans
1.26%
ROA
-247%
ROE
-282%
ROC
1.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
2.29M
Shs Float
2.18M
-
-
-
-
Target Price
-
52W Range
1.6-17.0
52W High
-89.71%
52W Low
+75%
RSI
40.05
Rel Volume
21.09
Avg Volume
356.93K
Volume
7.53M
Perf Week
-17.06%
Perf Month
-36.13%
Perf Quarter
-70.74%
Perf Half Y
-66.86%
-
-
-
-
Beta
2.12592
-
-
Volatility
0.21%, 0.24%
Prev Close
-20.81%
Price
1.75
Change
-57.32%

TENX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-6.27-4.35-1.351.33-1.58
Operating cash flow per share
-8.61-3.51-1.22-1.25-0.53
Free cash flow per share
-8.61-3.52-1.22-1.25-0.53
Cash per share
5.488.220.870.910.27
Book value per share
6.37.520.610.620.21
Tangible book value per share
6.37.520.610.960.21
Share holders equity per share
6.37.520.610.620.21
Interest debt per share
000.020.020.01
Market cap
9.03M1.83M8.43M17.06M13.19M
Enterprise value
7.42M-10.54M3.63M10.99M7.9M
P/E ratio
-1.02-0.27-11.73-0.41
Price to sales ratio
00000
POCF ratio
-0.74-0.33-1.12-1.84-1.21
PFCF ratio
-0.74-0.33-1.11-1.84-1.21
P/B Ratio
1.020.162.233.693.11
PTB ratio
1.020.162.233.693.11
EV to sales
00000
Enterprise value over EBITDA
-0.841.55-0.441.1-0.24
EV to operating cash flow
-0.611.92-0.48-1.18-0.73
EV to free cash flow
-0.611.91-0.48-1.18-0.73
Earnings yield
-0.98-3.72-10.58-2.46
Free cash flow yield
-1.35-3.01-0.9-0.54-0.82
Debt to equity
00000.04
Debt to assets
0.10.120.410.020.29
Net debt to EBITDA
0.181.820.58-0.610.16
Current ratio
7.998.512.443.213.64
Interest coverage
000-6.07K-34.49K
Income quality
1.370.810.9-0.940.33
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.33-0.84-0.03-0.03-0.05
Stock based compensation to revenue
00000
Graham number
29.827.154.314.322.71
ROIC
-1.04-0.59-2.23-1.92-7.39
Return on tangible assets
-0.89-0.51-1.321.36-5.42
Graham Net
4.797.220.450.890.19
Working capital
7.05M11.75M3.65M4.68M4.13M
Tangible asset value
00000
Net current asset value
7.05M11.75M3.59M6.67M3.94M
Invested capital
000.030.040.07
Average receivables
00000
Average payables
684.86K753.84K1.21M757.86K808.75K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1-0.58-2.232.13-7.65
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-0.15-0.13-0.11-0.11-0.11
Operating cash flow per share
-0.12-0.11-0.12-0.14-0.13
Free cash flow per share
-0.12-0.11-0.12-0.14-0.13
Cash per share
0.330.220.110.290.14
Book value per share
0.290.170.060.270.15
Tangible book value per share
0.290.170.060.270.15
Share holders equity per share
0.290.170.060.270.15
Interest debt per share
0.010.010.020.010.01
Market cap
44.61M26.21M20.42M7.56M4.48M
Enterprise value
36.57M20.92M18.04M663.81K881.31K
P/E ratio
-2.94-2.04-1.88-0.66-0.38
Price to sales ratio
00000
POCF ratio
-14.76-9.47-6.95-2.2-1.34
PFCF ratio
-14.75-9.46-6.94-2.2-1.34
P/B Ratio
6.166.1712.711.111.13
PTB ratio
6.166.1712.711.111.13
EV to sales
00000
Enterprise value over EBITDA
-9.69-6.57-6.7-0.23-0.31
EV to operating cash flow
-12.1-7.56-6.14-0.19-0.26
EV to free cash flow
-12.1-7.55-6.13-0.19-0.26
Earnings yield
-0.09-0.12-0.13-0.38-0.65
Free cash flow yield
-0.07-0.11-0.14-0.45-0.74
Debt to equity
0.030.040.10.020.02
Debt to assets
0.190.290.570.190.17
Net debt to EBITDA
2.131.660.882.441.24
Current ratio
5.873.641.755.66.54
Interest coverage
001.05K1.93K7.84K
Income quality
0.80.861.081.21.14
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.06-0.06-0.2300
Stock based compensation to revenue
00000
Graham number
0.990.690.390.830.61
ROIC
-0.51-0.731.540.410.72
Return on tangible assets
-0.43-0.54-0.73-0.34-0.62
Graham Net
0.270.150.030.220.11
Working capital
7.12M4.13M1.48M6.66M3.82M
Tangible asset value
00000
Net current asset value
6.91M3.94M1.32M6.53M3.73M
Invested capital
0.040.070.310.050.05
Average receivables
00000
Average payables
847.82K889.51K1.1M919.38K592.4K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.52-0.76-1.69-0.42-0.74
Capex per share
00000

TENX Frequently Asked Questions

What is Tenax Therapeutics, Inc. stock symbol ?

Tenax Therapeutics, Inc. is a US stock , located in Morrisville of Nc and trading under the symbol TENX

What is Tenax Therapeutics, Inc. stock quote today ?

Tenax Therapeutics, Inc. stock price is $1.75 today.

Is Tenax Therapeutics, Inc. stock public?

Yes, Tenax Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap